Endo and Penwest license Opana marketing rights to Valeant
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals has acquired the marketing rights to Opana ER (oxymorphone extended-release) in Canada, Australia and New Zealand. The firm will pay Endo Pharmaceuticals and Penwest Pharmaceuticals Can$2 million ($1.8 million) upfront for the pain product's rights.